Safety, pharmacokinetics, preliminary efficacy, pharmacodynamics, and immunogenicity of QX002N, an anti-IL-17A monoclonal antibody, after short-term treatment of active ankylosing spondylitis
This study was registered with Chinadrugtrials.org.cn (CTR20201277), the data of registration was in 20 Jul, 2020.
Authors
- Min Fang (ORCID: https://orcid.org/0000-0001-5241-6460)
- Min Wu (ORCID: https://orcid.org/0009-0007-3527-4262)
- Qianqian Li (ORCID: https://orcid.org/0000-0001-6961-771X)
- Hong Zhang (ORCID: https://orcid.org/0000-0002-4392-7370)
- Yanhua Ding (ORCID: https://orcid.org/0000-0002-0498-8939)
Institutions
- Jilin University (CN)
- Q Therapeutics (United States) (US)
- First Hospital of Jilin University (CN)
Publication Details
- Journal
- BMC Pharmacology and Toxicology
- Published
- 2025-05-19
- DOI
- https://doi.org/10.1186/s40360-025-00885-4
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00